| CAS NO: | 803647-40-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 265.27 |
|---|---|
| Formula | C12H15N3O4 |
| CAS No. | 803647-40-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 53.0 mg/mL (199.8 mM) |
| Water:<1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: 53.0 mg/mL (199.8 mM) | |
| SMILES | NSC59984; NSC-59984; NSC 59984; (E)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one |
| General | In nude mice bearing DLD-1 xenograft tumors, NSC59984 (45 mg/kg, i.p.) significantly represses tumor growth in a p73-dependent manner. |
|---|---|
| Animal model | Nude mice bearing DLD-1 xenograft tumors |
| Formulation | N/A |
| Dosages | 45 mg/kg |
| Administration | i.p. injection every 5 days |
| References | Zhang S, et al. Cancer Res. 2015, 75(18), 3842-3852. |
 Effects of NSC59984 injection on tumor growth and cell death in xenograft tumors in vivo. Zhang S, et al. Cancer Res. 2015, 75(18), 3842-3852. |  p73 is required for NSC59984 to restore the p53 pathway in mutant p53-expressing tumor cells. Zhang S, et al. Cancer Res. 2015, 75(18), 3842-3852. |  NSC59984 induces mutant p53 degradation via MDM2-mediated ubiquitination. Zhang S, et al. Cancer Res. 2015, 75(18), 3842-3852. |
m.cnreagent.com